Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Jefferies Downgrades Scholar Rock Holding to Hold, Lowers Price Target to $28
Jefferies analyst Michael Yee downgrades Scholar Rock Holding (NASDAQ:SRRK) from Buy to Hold and lowers the price target from $52 to $28.
Scholar Rock Holding Q3 EPS $(1.02) Down From $(0.79) YoY, Sales $5.46M Up From $3.04M YoY
Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(1.02) per share. This is a 29.11 percent decrease over losses of $(0.79) per share from the same period last year. The company reported $5.46 million in
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
Scholar Rock (NASDAQ: SRRK) today announced an e-poster presentation of clinical results from the TOPAZ Phase 2 trial (NCT03921528) that evaluated apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA) at the 25th World Congress of Neurology (WCN) taking place October 3-7, 2021.
Scholar Rock Presents Exploratory Responder Analysis On Efficacy Data From Apitegromab TOPAZ Phase 2 Trial At Child Neurology Society Annual Meeting
Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a late breaker poster
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
Scholar Rock Presents Additional Data Analyses From Apitegromab TOPAZ Phase 2 Trial At World Muscle Society 2021 Virtual Congress
Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations
48 Biggest Movers From Yesterday
Gainers
Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients.